As providers struggle to receive real-time and accurate snapshots of cardiovascular (CV) disease risk and determine whether a person is headed for a CV event, next-generation testing, indicating the future likelihood of a major CV event, is required to improve clinical outcomes.
Proteomic testing can reveal multiple answers to clinical questions that allow providers to better predict, monitor, and prevent the escalation of CV disease. This allows providers to move the needle away from the practice of late-stage treatment and toward treating at-risk patients sooner and before a major CV event.
Join us on Wednesday, November 9 to learn the capabilities of proteomics, how comprehensive protein detection technology can accurately predict major CV events, and how proteomic testing can ultimately improve outcomes.
During this webinar, you’ll learn:
Founded in 2000, SomaLogic is a global leader in proteomics. Powered by an industry-leading technology platform and one of the largest clinical proteomic database in the world, we aim to revolutionize precision medicine to help address unmet medical needs.
We understand the importance of real-time data and actionable information when it comes to health, which is why we provide patients with knowledge on their current health status through analyzing their personal protein data.
SomaLogic’s pioneering platform provides more coverage of the proteome than any other technology. SomaLogic currently measures approximately 7,000 proteins, more than twice as many as other proteomic technology platforms, and we are quickly moving toward 10,000 proteins. That’s half of the approximately 20,000 proteins in your body.
The proprietary SomaScan® Assay measures proteins with high specificity, low variance and high reproducibility, which enables the possibility of faster, more precise drug discovery.
SomaLogic’s A.I. and machine learning-powered bioinformatics algorithms, operated in tandem with the company’s database of more than 450,000 protein samples, helped to create a growing suite of SomaSignal™ tests. These tests are clinical proteomic diagnostics that provide additional insights into the current health status of patients and the future risk of conditions and diseases with a small blood sample.
SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory.